Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates
Candace L. Haddox(Rutgers, The State University of New Jersey), Suzanne George(Dana-Farber Cancer Institute), Emanuele Mazzola(Dana-Farber Cancer Institute), Priscilla Merriam(Dana-Farber Cancer Institute), Jason L. Weirather(Dana-Farber Cancer Institute), Joanna Bagińska(Dana-Farber Cancer Institute), Adrián Mariño‐Enríquez(Harvard University Press), Jeffrey A. Morgan(Sheba Medical Center), Jia‐Ren Lin(Harvard University), Michael J. Nathenson(Harvard University), Peter K. Sorger(Harvard University Press), Allison Nau(Dana-Farber Cancer Institute), Edwin Choy(Massachusetts General Hospital), Andrew J. Wagner(Dana-Farber Cancer Institute), Gregory M. Coté(Harvard University), Sandro Santagata(Harvard University)
Cited by 35
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Copper induces cell death by targeting lipoylated TCA cycle proteins
|Science|2022|4.6k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.5k
Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota
|Nature Biotechnology|2016|873